Picture [LSUS] – The Business Web Portal 650x65px
Document › Details

Alligator Bioscience AB. (6/14/10). "Press Release: Alligator Bioscience AB Appoints Sibylle Lenz as Chief Executive Officer. Internationally Experienced Pharmaceutical Executive Will Join Alligator Bioscience AG on 1st August 2010". Lund.

Region Region Lund
  Country Sweden
Organisations Organisation Alligator Bioscience AB (Nasdaq Stockholm: ATORX)
  Group Alligator Bioscience (Group)
  Organisation 2 Dako A/S
Product Product FIND® technology (Fragment INduced Diversity)

Alligator Bioscience AB, a privately owned biotech company focusing on optimization
of biopharmaceuticals using its proprietary protein optimization technology FIND®,
announced today that it has appointed Sibylle Lenz, Pharm. Dr, as its new Chief
Executive Officer (CEO). Mrs Lenz, who joins Alligator Bioscience from Dako A/S and
who previously has had a long successful career at H. Lundbeck A/S, has significant
senior management experience in the pharmaceutical industry and has been
appointed to lead the Company as it embarks on a new phase of international clinical
and commercial development. Mrs Lenz will take up her position on 1st August 2010.

Sibylle Lenz is an experienced pharmaceutical executive who has held senior
positions in the diagnostics and pharmaceutical industry. She joins Alligator
Bioscience from Dako A/S, a cancer diagnostics company where she was Vice
President, Corporate Business Development.

From 2001 to 2008 Mrs Lenz held a number of senior international commercial
positions in H. Lundbeck A/S and prior to that Mrs Lenz gained more than ten years
of experience in different research and development positions, also in H. Lundbeck
A/S. Mrs Lenz holds a PhD specialized in medicinal chemistry from the Danish
University of Pharmaceutical Sciences.

"I am delighted to welcome Sibylle Lenz to Alligator Bioscience," said Mats Grahn,
Alligator Biosciences Chairman. "She is an entrepreneurial business leader who has
succeeded in building winning teams and delivered strong performance wherever she
has worked. I am confident she will be equally successful in taking Alligator
Bioscience forward as an innovative company in the field of creating and
commercializing new drug candidates."

Sibylle Lenz commented: "I look forward to joining Alligator Bioscience at a time of
great potential. The Company has achieved promising preclinical data with ADC-
1004, a selective C5a receptor antagonist for the treatment of ischemic reperfusion
injury and I believe this project can be brought successfully to market through
partnerships on an international basis. Furthermore, accelerating IMCAN, the
platform for cancer immunotherapy, will be a cornerstone in Alligator Biosciences
future. I believe my commercial pharmaceutical experience will help us to establish
and implement a winning international business strategy".

Record changed: 2016-03-20


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Alligator Bioscience (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 650x65px

» top